Stockscreener 앱 받기
13.36
1.44%
0.19
시간 외 거래:
13.45
0.09
+0.67%
전일 마감가:
$13.17
열려 있는:
$13.04
하루 거래량:
3.29M
Relative Volume:
3.74
시가총액:
$1.22B
수익:
$802.20M
순이익/손실:
$-155.20M
주가수익비율:
-3.9762
EPS:
-3.36
순현금흐름:
$-141.30M
1주 성능:
-7.42%
1개월 성능:
-12.68%
6개월 성능:
-43.87%
1년 성능:
-34.25%
1일 변동 폭
$13.04
$13.56
1주일 범위
$12.87
$14.54
52주 변동 폭
$12.87
$29.30
Myriad Genetics Inc Stock (MYGN) Company Profile
명칭
Myriad Genetics Inc
전화
801-584-3600
주소
322 NORTH 2200 WEST, SALT LAKE CITY, UT
MYGN을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
MYGN
Myriad Genetics Inc
|
13.36 | 1.22B | 802.20M | -155.20M | -141.30M | -1.81 |
|
TMO
Thermo Fisher Scientific Inc
|
524.05 | 200.45B | 42.37B | 6.14B | 7.78B | 15.95 |
|
DHR
Danaher Corp
|
228.55 | 165.08B | 23.74B | 3.89B | 4.98B | 5.24 |
|
A
Agilent Technologies Inc
|
134.51 | 38.36B | 6.51B | 1.29B | 1.37B | 4.42 |
|
IQV
Iqvia Holdings Inc
|
197.27 | 35.80B | 15.32B | 1.41B | 1.96B | 7.62 |
|
IDXX
Idexx Laboratories Inc
|
412.26 | 33.76B | 3.84B | 866.24M | 792.60M | 10.37 |
Myriad Genetics Inc Stock (MYGN) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-12-10 | 개시 | UBS | Neutral |
| 2024-12-09 | 다운그레이드 | Leerink Partners | Outperform → Market Perform |
| 2024-09-19 | 개시 | Morgan Stanley | Equal-Weight |
| 2024-08-28 | 개시 | Wells Fargo | Overweight |
| 2024-06-27 | 개시 | Scotiabank | Sector Outperform |
| 2024-06-03 | 재개 | Jefferies | Underperform |
| 2024-05-08 | 업그레이드 | Leerink Partners | Market Perform → Outperform |
| 2023-12-21 | 재개 | Piper Sandler | Neutral |
| 2023-12-19 | 개시 | Wells Fargo | Equal Weight |
| 2023-12-14 | 개시 | Guggenheim | Buy |
| 2023-12-13 | 개시 | Wolfe Research | Outperform |
| 2023-07-05 | 재개 | JP Morgan | Underweight |
| 2023-05-23 | 업그레이드 | Goldman | Sell → Buy |
| 2023-01-18 | 업그레이드 | Raymond James | Mkt Perform → Outperform |
| 2022-10-06 | 개시 | Stephens | Equal-Weight |
| 2021-10-15 | 재개 | Cowen | Market Perform |
| 2021-06-15 | 개시 | Raymond James | Mkt Perform |
| 2021-06-03 | 개시 | Goldman | Sell |
| 2019-09-26 | 다운그레이드 | BofA/Merrill | Neutral → Underperform |
| 2019-08-14 | 다운그레이드 | Piper Jaffray | Overweight → Neutral |
| 2019-08-02 | 업그레이드 | BofA/Merrill | Underperform → Neutral |
| 2019-08-01 | 업그레이드 | Barclays | Underweight → Equal Weight |
| 2019-07-29 | 다운그레이드 | Needham | Strong Buy → Hold |
| 2019-07-09 | 다운그레이드 | Cowen | Outperform → Market Perform |
| 2019-03-12 | 재확인 | Needham | Strong Buy |
| 2019-01-03 | 개시 | Needham | Strong Buy |
| 2018-11-30 | 업그레이드 | Goldman | Sell → Neutral |
| 2018-10-10 | 업그레이드 | Piper Jaffray | Neutral → Overweight |
| 2018-07-11 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2018-03-21 | 업그레이드 | Morgan Stanley | Underweight → Equal-Weight |
| 2018-01-29 | 개시 | Goldman | Sell |
| 2018-01-22 | 재확인 | Barclays | Equal Weight |
| 2018-01-05 | 개시 | BTIG Research | Buy |
| 2017-10-02 | 재개 | Leerink Partners | Mkt Perform |
| 2017-08-09 | 재확인 | Barclays | Equal Weight |
| 2017-02-08 | 업그레이드 | Ladenburg Thalmann | Sell → Neutral |
| 2017-01-18 | 개시 | Deutsche Bank | Sell |
| 2016-10-10 | 다운그레이드 | Ladenburg Thalmann | Neutral → Sell |
모두보기
Myriad Genetics Inc 주식(MYGN)의 최신 뉴스
Barclays PLC Raises Stake in Myriad Genetics, Inc. (NASDAQ:MYGN) - MarketBeat
MYGN Stock Might Gain From the New Recognition of RiskScore Study - Yahoo Finance
PARP Inhibitor Biomarkers Market Investment Outlook: Industry - openPR
Pancreatic Cancer Market Analysis 2024: Trends, Growth, and Key - openPR
Myriad Genetics’ RiskScore Study Named One of the Top 10 - GlobeNewswire
Myriad Genetics' Breakthrough Cancer Test Named Top 10 Genomic Advance by Leading Journal - StockTitan
Hereditary Cancer Testing Market: Pioneering Early Detection and Prevention Strategies - openPR
Myriad Genetics (NASDAQ:MYGN) Sets New 1-Year LowTime to Sell? - MarketBeat
Myriad Genetics stock hits 52-week low at $13.86 amid challenges - Investing.com Canada
Is Myriad Genetics Stock a Smart Hold for Your Portfolio Right Now? - Yahoo Finance
MYGN INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Myriad Genetics, Inc. and Encourages Investors to Contact the Firm - The Eastern Progress Online
Myriad Genetics stock hits 52-week low at $13.86 amid challenges By Investing.com - Investing.com South Africa
Clinical Oncology Next Generation Sequencing Market Top - openPR
How To Trade (MYGN) - Stock Traders Daily
State Street Corp Buys 359,685 Shares of Myriad Genetics, Inc. (NASDAQ:MYGN) - MarketBeat
Myriad Genetics (NASDAQ:MYGN) Price Target Lowered to $13.00 at Bank of America - MarketBeat
Why Myriad Genetics, Inc. Shares Soared - AOL
Analysts Offer Predictions for Myriad Genetics Q1 Earnings - MarketBeat
Myriad Genetics Provides Update on Discussions with UnitedHealthcare regarding Medical Policy for Pharmacogenetic Testing - The Manila Times
Myriad Genetics Provides Update on Discussions with - GlobeNewswire
Myriad Genetics Fights to Preserve GeneSight Coverage as UnitedHealthcare Plans 2025 Restrictions - StockTitan
Myriad Genetics Expands Board of Directors with Election of Mark S. Davis as New Board Member - The Manila Times
New NCCN Guidelines Boost Myriad Genetics' Prolaris: Stock To Gain? - Barchart
Myriad Genetics' Portfolio Elevated by Updated NCCN Prostate Cancer Guidelines - The Manila Times
Myriad Genetics’ Portfolio Elevated by Updated NCCN Prostate Cancer Guidelines - GlobeNewswire
Myriad Genetics (NASDAQ:MYGN) Stock Rating Lowered by Leerink Partnrs - MarketBeat
Myriad Genetics (NASDAQ:MYGN) Coverage Initiated by Analysts at UBS Group - MarketBeat
Disciplined Growth Investors Inc. MN Purchases 440,107 Shares of Myriad Genetics, Inc. (NASDAQ:MYGN) - MarketBeat
New NCCN Guidelines Boost Myriad Genetics' Prolaris: Stock to Gain? - Yahoo Finance
Cancer Biopsy Market Trends, Key Drivers, and Regional Outlook - openPR
PARP Inhibitor Biomarkers Market Key Players AnalysisMyriad - openPR
Pharmacogenomics Global Market Report: Key Insights and Market - openPR
Myriad Genetics to Present New Data at San Antonio Breast Cancer Symposium - The Manila Times
Myriad Genetics Unveils Breakthrough Breast Cancer Detection Tools at SABCS 2024 - StockTitan
Myriad Genetics (NASDAQ:MYGN) Stock Rating Lowered by Leerink Partners - MarketBeat
NCCN Prostate Cancer Guidelines Reinforce Status of Myriad Genetics' Prolaris® Test as an 'Advanced Tool' Recommended for Prognostic Assessment - The Manila Times
NCCN Prostate Cancer Guidelines Reinforce Status of Myriad - GlobeNewswire
Myriad Genetics' Prolaris Test Retains Elite NCCN Status for 10th Year in Prostate Cancer Diagnosis - StockTitan
Wellington Management Group LLP Sells 1,545,842 Shares of Myriad Genetics, Inc. (NASDAQ:MYGN) - MarketBeat
Myriad Genetics (NASDAQ:MYGN) Hits New 12-Month LowWhat's Next? - MarketBeat
Shareholders in Myriad Genetics (NASDAQ:MYGN) have lost 41%, as stock drops 7.0% this past week - Simply Wall St
Myriad Genetics stock hits 52-week low at $14.54 amid market shifts - Investing.com Canada
RSI Alert: Myriad Genetics (MYGN) Now Oversold - Nasdaq
Myriad Genetics stock hits 52-week low at $14.54 amid market shifts By Investing.com - Investing.com South Africa
Point72 Asset Management L.P. Grows Position in Myriad Genetics, Inc. (NASDAQ:MYGN) - MarketBeat
Verition Fund Management LLC Has $2.44 Million Holdings in Myriad Genetics, Inc. (NASDAQ:MYGN) - MarketBeat
Charles Schwab Investment Management Inc. Acquires 41,374 Shares of Myriad Genetics, Inc. (NASDAQ:MYGN) - MarketBeat
How to Take Advantage of moves in (MYGN) - Stock Traders Daily
Edgestream Partners L.P. Makes New Investment in Myriad Genetics, Inc. (NASDAQ:MYGN) - MarketBeat
MYGN Beats on Q3 Earnings and Revenues, Raises '24 EPS View - MSN
Fisher Asset Management LLC Boosts Position in Myriad Genetics, Inc. (NASDAQ:MYGN) - MarketBeat
Myriad Genetics Inc (MYGN) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.72%
자본화:
|
볼륨(24시간):